Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase <i>Erwinia chrysanthemi</i> nork Wing H. Tong, Carmelo Rizzari

Testu osoa

Comment on Association of <I>FLT3</i>-internal duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis nork Wing H. Tong, Jan W. Schoones

Testu osoa

Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” nork Wing H. Tong MD, PhD, MSc

Testu osoa

Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase nork Wing H. Tong, Rob Pieters, Wim J.E. Tissing, Inge M. van der Sluis

Testu osoa

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia nork Wing H. Tong, Rob Pieters, Hester A. de Groot-Kruseman, Wim C. J. Hop, Joachim Boos, Wim J. E. Tissing, Inge M. van der Sluis

Testu osoa

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy nork Wing H. Tong, Inge M. van der Sluis, Cathelijne J.M. Alleman, Raphaële R.L. van Litsenburg, Gertjan J. L. Kaspers, Rob Pieters, Carin A. Uyl-de Groot

Testu osoa